Cytocom, Inc. (CBLI) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Cytocom, Inc. (CBLI) Healthcare & Pipeline Overview

Cytocom, Inc. is a biopharmaceutical company specializing in immune system activation through its proprietary Toll-like immune receptor activator platform. Headquartered in Buffalo, New York, the firm develops drug candidates like Entolimod for radiation countermeasures and immuno-oncology, addressing serious medical needs within the biotechnology sector.

What Is the Investment Thesis for CBLI?

Cytocom, Inc. presents an investment profile centered on its early-to-mid-stage biopharmaceutical pipeline, particularly its focus on immune system activation. The core value driver is the potential of its lead candidate, Entolimod, which targets two distinct yet critical markets: radiation countermeasures and immuno-oncology. Success in clinical trials for Entolimod, especially in securing regulatory approvals for either indication, would represent a significant growth catalyst. Additionally, the company's broader platform of Toll-like immune receptor activators, encompassing candidates like CBLB612, Mobilan, and CBL0137, offers diversification and multiple shots on goal within the immunology and oncology therapeutic areas. However, as an R&D-intensive company with a reported profit margin of -912.2% and a small team of 15 employees, Cytocom faces substantial execution risks, including clinical trial failures, regulatory hurdles, and the need for significant future funding. The company's current market capitalization of $226M reflects its early-stage nature and the inherent risks associated with drug development, making its valuation highly sensitive to pipeline progress and strategic partnerships.

Based on FMP financials and quantitative analysis

CBLI Key Highlights

• Market Capitalization stands at $0.23 billion, reflecting its position as a smaller, development-stage biopharmaceutical company.
• Profit Margin is reported at -912.2%, indicating significant ongoing research and development expenses without corresponding revenue generation.
• Gross Margin is 100.0%, which is typical for a company primarily engaged in R&D with minimal or no product sales.
• Beta of 0.68 suggests lower volatility compared to the broader market, potentially due to its specific R&D focus and early stage.
• The company employs 15 full-time employees, highlighting a lean operational structure focused on specialized scientific and clinical development.

Who Are CBLI's Competitors?

CBLI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CBLI's Key Strengths?

• Proprietary platform of Toll-like immune receptor activators with broad applications.
• Advanced product candidate, Entolimod, targeting dual high-impact indications (radiation injury, immuno-oncology).
• Diverse pipeline including CBLB612, Mobilan, and CBL0137, offering multiple therapeutic approaches.
• Focused R&D strategy in immune system activation to address serious medical needs.

What Are CBLI's Weaknesses?

• Significant negative profit margin (-912.2%), indicating substantial R&D costs without revenue.
• Small employee base (15 full-time employees), potentially limiting operational scale and speed.
• Reliance on successful clinical trial outcomes for pipeline candidates, which are inherently uncertain.
• Early-stage nature of most product candidates, implying long development timelines and high risk.

What Could Drive CBLI Stock Higher?

• **Progress in Entolimod Clinical Development.** Any announcement regarding positive data from ongoing or planned clinical trials for Entolimod, either as a radiation countermeasure or an immuno-oncology agent, would be a significant catalyst for Cytocom, Inc.
• **Regulatory Milestones for Pipeline Candidates.** Achievement of key regulatory milestones, such as IND (Investigational New Drug) application approvals or Fast Track designations for any of its drug candidates (Entolimod, CBLB612, Mobilan, CBL0137), would signal progress and validation.
• **Strategic Partnerships and Collaborations.** The formation of new research collaborations or licensing agreements with larger pharmaceutical companies could provide non-dilutive funding and external validation for Cytocom, Inc.'s technology platform and pipeline.
• **Advancement of CBL0137 in Cancer Indications.** Continued preclinical or early clinical progress for CBL0137, particularly demonstrating its multi-targeted mechanism's efficacy in various cancer models, could broaden its therapeutic potential and attract further investment.

What Are the Key Risks for CBLI?

• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• **Clinical Trial Failures.** The primary risk for Cytocom, Inc. is the potential for its drug candidates, including Entolimod, CBLB612, Mobilan, and CBL0137, to fail in preclinical or clinical trials due to lack of efficacy or unacceptable safety profiles. Such failures would significantly devalue the company's pipeline and future prospects.
• **Regulatory Approval Uncertainty.** As a biopharmaceutical company, Cytocom, Inc. faces inherent risks associated with the stringent and unpredictable regulatory approval processes by health authorities like the FDA. Delays or outright rejections of its drug candidates could severely impact its ability to commercialize products.
• **Funding and Liquidity Risks.** With a negative profit margin of -912.2%, Cytocom, Inc. is highly dependent on external funding to sustain its extensive research and development activities. Inability to secure sufficient capital through equity financing or partnerships could impede pipeline progression and operational continuity.
• **Intense Competition.** The fields of immuno-oncology and immunology are highly competitive, with numerous large pharmaceutical companies and well-funded biotechnology firms developing similar or superior therapies. Cytocom, Inc.'s ability to differentiate its products and gain market share is a significant challenge.
• **Intellectual Property Challenges.** The company's success relies on its ability to protect its intellectual property. Challenges to its patents, or the inability to obtain new patents, could undermine its competitive position and allow competitors to develop similar products.

What Are the Growth Opportunities for CBLI?

• Growth opportunity 1: **Advancement of Entolimod as a Radiation Countermeasure.** Entolimod, an immuno-stimulatory agent, is under development as a radiation countermeasure. The global market for medical countermeasures, including those for radiation exposure, is driven by geopolitical concerns and potential public health emergencies. Successful clinical development and regulatory approval for Entolimod in this indication could position Cytocom, Inc. to address a critical, specialized market, potentially through government procurement contracts. The timeline for such development is typically multi-year, involving rigorous testing to demonstrate efficacy and safety in relevant models, offering a significant, albeit long-term, revenue pathway.
• Growth opportunity 2: **Expansion of Entolimod into Immuno-Oncology.** Beyond radiation countermeasures, Entolimod is also being developed as an immunotherapy for oncology. Entolimod's mechanism as an immuno-stimulatory agent could offer novel therapeutic options, either as a monotherapy or in combination with existing cancer treatments. Successful clinical trials demonstrating efficacy and safety in various cancer types would unlock access to a vast and lucrative market, providing substantial growth potential for Cytocom, Inc. over the next decade.
• Growth opportunity 3: **Development of CBLB612 for Innate Immune System Modulation.** CBLB612 is a compound based on a natural activator of the toll-like receptor 2 (TLR2)/toll-like receptor 6 (TLR6) heterodimeric receptor. Modulation of innate immune pathways holds promise for treating a range of inflammatory, infectious, and autoimmune diseases. Identifying specific indications where TLR2/TLR6 activation provides a therapeutic advantage could open new market segments for Cytocom, Inc. The market for immunomodulators is substantial, and a novel, targeted approach like CBLB612 could capture a niche within this broad therapeutic area, with development timelines dependent on preclinical and clinical success.
• Growth opportunity 4: **Leveraging Mobilan for TLR5 Agonism.** Mobilan is a recombinant non-replicating adenovirus designed to direct the expression of TLR5 and its agonistic ligand. TLR5 activation is known to induce potent immune responses, making it a target for various therapeutic applications, including oncology and infectious diseases. Successful development of Mobilan could provide Cytocom, Inc. with a unique viral-vector-based immunotherapeutic. The market for gene and cell therapies, which includes viral vector approaches, is experiencing rapid growth, indicating a receptive environment for innovative delivery mechanisms and immune activation strategies. This represents a significant long-term growth avenue.
• Growth opportunity 5: **Advancing CBL0137 for Multi-Targeted Cancer Treatment.** CBL0137 is a small molecule with a multi-targeted mechanism of action, potentially useful for treating various types of cancer. Multi-targeted therapies are increasingly sought after in oncology to overcome resistance and address complex tumor biology. If CBL0137 demonstrates efficacy across multiple cancer indications, it could address a broad patient population and command a significant share in the global oncology market, which is projected to continue its robust expansion. The development and commercialization of such a broad-spectrum oncology agent would be a transformative growth driver for Cytocom, Inc. within the next five to ten years.

What Opportunities Does CBLI Have?

• Growing global market for immuno-oncology therapies and radiation countermeasures.
• Potential for strategic partnerships or licensing agreements to fund development and accelerate commercialization.
• Expansion of pipeline into additional indications or combination therapies for existing candidates.
• Leveraging its platform to discover new drug candidates targeting other immune-related diseases.

What Threats Does CBLI Face?

• High risk of clinical trial failures, which could lead to significant financial losses and delays.
• Intense competition from larger pharmaceutical companies and other biotechnology firms.
• Stringent and complex regulatory approval processes for novel drug candidates.
• Need for substantial additional funding to support ongoing research and development activities.
• Patent expirations or challenges to intellectual property rights for its drug candidates.

What Are CBLI's Competitive Advantages?

• Proprietary platform of Toll-like immune receptor activators, offering a distinct approach to immune modulation.
• Advanced product candidate, Entolimod, targeting niche and high-value indications like radiation countermeasures.
• Diverse pipeline of drug candidates (CBLB612, Mobilan, CBL0137) exploring different immune pathways and cancer mechanisms.
• Specialized expertise in developing immuno-stimulatory agents and understanding innate immune responses.
• Potential for strong intellectual property protection around its novel compounds and therapeutic applications.

What Does CBLI Do?

Cytocom, Inc., trading under the ticker CBLI, operates as a biopharmaceutical company primarily engaged in the research and development of novel drug candidates. The company, headquartered in Buffalo, New York, focuses its efforts on developing innovative approaches to activate the immune system, aiming to address significant unmet medical needs. Its core technological foundation is a platform of Toll-like immune receptor activators, which holds promising applications in two critical areas: the mitigation of radiation injury and the field of immuno-oncology. The firm's most advanced product candidate is Entolimod, an immuno-stimulatory agent currently under development. Entolimod is being pursued for dual indications, serving as both a potential radiation countermeasure and a therapeutic immunotherapy for various oncology indications. Beyond Entolimod, Cytocom, Inc. maintains a pipeline of other distinct product candidates. These include CBLB612, a compound designed to activate the toll-like receptor 2 (TLR2)/toll-like receptor 6 (TLR6) heterodimeric receptor, a specific component of the innate immune system. Another candidate, Mobilan, is a recombinant non-replicating adenovirus engineered to direct the expression of TLR5 and its agonistic ligand. Furthermore, CBL0137 represents a small molecule with a multi-targeted mechanism of action, which Cytocom, Inc. believes may offer therapeutic utility for the treatment of various types of cancer. The company employs approximately 15 full-time employees, reflecting its focused R&D-centric operational model within the highly specialized biotechnology landscape.

What Products and Services Does CBLI Offer?

• Conduct research and development of biopharmaceutical drugs.
• Develop approaches to activate the immune system to address serious medical needs.
• Utilize a platform of Toll-like immune receptor activators.
• Develop Entolimod as an immuno-stimulatory agent for radiation countermeasures.
• Develop Entolimod as an immunotherapy for various oncology indications.
• Research CBLB612, a compound activating TLR2/TLR6 heterodimeric receptors.
• Develop Mobilan, a recombinant adenovirus expressing TLR5 and its ligand.
• Investigate CBL0137, a small molecule for treating various types of cancer.

How Does CBLI Make Money?

• Primary focus on preclinical and clinical research and development of novel drug candidates.
• Aims to generate value through the progression of its drug pipeline towards regulatory approval.
• Potential future revenue streams from commercialization of approved drugs, either directly or through partnerships.
• May pursue licensing agreements or collaborations for its proprietary platform or specific drug candidates.
• Operates with an R&D-intensive model, requiring significant investment in scientific discovery and clinical trials.

What Industry Does CBLI Operate In?

Cytocom, Inc. operates within the highly specialized and competitive Biotechnology industry, a sub-sector of Healthcare. This industry is characterized by extensive research and development, long product development cycles, and significant regulatory hurdles. The company's focus on activating the immune system positions it within the growing fields of immunology and immuno-oncology, which are areas of intense innovation and investment due to their potential to treat previously intractable diseases. Market trends indicate a strong demand for novel therapies in cancer treatment and biodefense, where radiation countermeasures are critical. Cytocom's platform of Toll-like immune receptor activators places it among numerous firms exploring innate immune system modulation. The competitive landscape includes large pharmaceutical companies with extensive resources and smaller biotech firms, all vying for breakthroughs and market share in specific therapeutic niches. Cytocom's differentiation lies in its specific pipeline candidates like Entolimod, CBLB612, Mobilan, and CBL0137, each targeting distinct immune pathways or disease mechanisms.

Who Are CBLI's Key Customers?

• Potential future customers include government agencies for radiation countermeasures (e.g., for Entolimod).
• Healthcare providers and oncology centers for cancer therapies (e.g., Entolimod, CBL0137).
• Pharmaceutical companies seeking partnerships or licensing opportunities for novel immune activators.
• Patients suffering from specific oncology indications or requiring radiation injury mitigation.
• Research institutions and academic collaborators in immunology and oncology fields.

How Cytocom, Inc. Is Valued

Cytocom, Inc. carries a market capitalization of $226M, placing it in the micro-cap category. Relative to its peer group, CBLI's quantitative score of 50/100 is below the peer average of 72/100.

Key Financial Metrics

Its free cash flow yield is -1.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 7.60 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -6.1%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 1/9Financial Health

Cytocom, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

CBLI Financials

CBLI Latest News

CBLI Analyst Consensus

CBLI MoonshotScore

CBLI Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources